Sign in
Taking peopleNo phase

A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection

Key facts

Who runs it
TTY Biopharm
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
480 people, planned
Started
26 Nov 2025
Expected to end
30 Nov 2028
Type of study
Observational, 2 groups
Record updated
9 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patient ≥ 18 years of age
  • Patient diagnosed with bacterial pneumonia and/or bacteremia, or other physician judged serious infection (except urinary tract infection, UTI) caused by Carbapenem-Resistant Gram-Negative Bacteria (CR-GNB); CR-GNB: Resistant to at least one of the carbapenem antibiotics or produce a carbapenemase (an enzyme that can make them resistant to carbapenem antibiotics); Diagnosis Criteria of HABP/VABP:; Met the clinical diagnosis criteria for HABP/VABP. HABP: Acute bacterial pneumonia in a subject hospitalized for more than 48 hours or developing within 7 days after discharge from a hospital. Subject could have experienced acute respiratory failure and required mechanical ventilation for HABP; VABP: Acute bacterial pneumonia in a subject receiving mechanical ventilation via an endotracheal (or nasotracheal) tube for a minimum of 48 hours; ≥ 1 of the following clinical features: new onset or worsening of pulmonary symptoms or signs, hypoxemia, need for acute changes in the ventilator support system to enhance oxygenation, new onset of or increase in suctioned respiratory secretions; ≥ 1 of the following signs: documented fever, hypothermia, WBC ≥ 10,000 cells/mm3, WBC ≤ 4500 cells/mm3, >15% immature neutrophils(bands); CXR or lung CT: presence of new or progressive infiltrates suggestive of bacterial pneumonia; Diagnosis Criteria of BSI/Bacteremia: the BSI/sepsis category included bacteremia or sepsis caused by infections other than HABP/VABP, or UTI:; Documented BSI caused by a carbapenem-resistant Gram-negative pathogen; or; Systemic response to infection, meeting the clinical criteria of SIRS and an identified infection source (eg, severe skin infection, intra-abdominal infection) caused by a carbapenem-resistant Gram-negative pathogen
  • Patient received intravenous polymyxin B or CMS treatment for ≥72 h
  • Administration of polymyxin B or CMS within 7 days from the infection onset day; Infection onset day: The date of specimen collection for index pathogen

Who cannot take part

  • Patient with bacteremia caused by urinary tract infection
  • Patient has infectious disease (s) caused by the following gram-negative bacteria which are known to have no response to polymyxin B and/or colistin treatment: Proteus spp., Providencia spp., Morganella spp., Serratia marcescens, Burkholderia spp., and Neisseria spp
  • CR-GNB known to be resistant to polymyxin B or CMS
  • Intravenous administration of polymyxin B or colistin more than 28 days
  • Both the treatment efficacy and safety could not be evaluated

This trial is currently available in Taiwan.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a retrospective, observational, post-marketing study to evaluate the clinical response, microbiological response, mortality, and safety of intravenous polymyxin B and colistin methanesulfonate in patients with carbapenem-resistant gram-negative bacterial infection. Subgroup analysis by sites of infection, infectious pathogens, and baseline renal function will also be performed.

The 2 groups in the trial

  • Experiment: Polymyxin B
  • Comparator: colistin methanesulfonate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Retrospective, Observational, Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Infusions Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
Record updated
9 March 2026